Seoyoung C Kim1, Sebastian Schneeweiss2, Niteesh Choudhry3, Jun Liu3, Robert J Glynn3, Daniel H Solomon4. 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Mass; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Mass; Department of Epidemiology, Harvard School of Public Health, Boston, Mass. Electronic address: skim62@partners.org. 2. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Mass; Department of Epidemiology, Harvard School of Public Health, Boston, Mass. 3. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Mass. 4. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Mass; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Mass.
Abstract
BACKGROUND: Hyperuricemia and gout are associated with an increased risk of cardiovascular disease (CVD). It is unknown whether treating hyperuricemia with xanthine oxidase inhibitors (XOIs), including allopurinol and febuxostat, modifies cardiovascular risks. METHODS: We used US insurance claims data to conduct a cohort study among gout patients, comparing XOI initiators with non-users with hyperuricemia defined as serum uric acid level ≥6.8 mg/dL. We calculated incidence rates of a composite nonfatal cardiovascular outcome that included myocardial infarction, coronary revascularization, stroke, and heart failure. Propensity score (PS)-matched Cox proportional hazards regression compared the risk of composite cardiovascular endpoint in XOI initiators vs those with untreated hyperuricemia, controlling for baseline confounders. In a subgroup of patients with uric acid levels available, PS-matched Cox regression further adjusted for baseline uric acid levels. RESULTS: There were 24,108 PS-matched pairs with a mean age of 51 years and 88% male. The incidence rate per 1000 person-years for composite CVD was 24.1 (95% confidence interval [CI] 22.6-26.0) in XOI initiators and 21.4 (95% CI, 19.8-23.2) in the untreated hyperuricemia group. The PS-matched hazard ratio for composite CVD was 1.16 (95% CI, 0.99-1.34) in XOI initiators vs those with untreated hyperuricemia. In subgroup analyses, the PS-matched hazard ratio for composite CVD adjusted for serum uric acid levels was 1.10 (95% CI, 0.74-1.64) among XOI initiators. CONCLUSIONS: Among patients with gout, initiation of XOI was not associated with an increased or decreased cardiovascular risk compared with those with untreated hyperuricemia. Subgroup analyses adjusting for baseline uric acid levels also showed no association between XOI and cardiovascular risk.
BACKGROUND:Hyperuricemia and gout are associated with an increased risk of cardiovascular disease (CVD). It is unknown whether treating hyperuricemia with xanthine oxidase inhibitors (XOIs), including allopurinol and febuxostat, modifies cardiovascular risks. METHODS: We used US insurance claims data to conduct a cohort study among goutpatients, comparing XOI initiators with non-users with hyperuricemia defined as serum uric acid level ≥6.8 mg/dL. We calculated incidence rates of a composite nonfatal cardiovascular outcome that included myocardial infarction, coronary revascularization, stroke, and heart failure. Propensity score (PS)-matched Cox proportional hazards regression compared the risk of composite cardiovascular endpoint in XOI initiators vs those with untreated hyperuricemia, controlling for baseline confounders. In a subgroup of patients with uric acid levels available, PS-matched Cox regression further adjusted for baseline uric acid levels. RESULTS: There were 24,108 PS-matched pairs with a mean age of 51 years and 88% male. The incidence rate per 1000 person-years for composite CVD was 24.1 (95% confidence interval [CI] 22.6-26.0) in XOI initiators and 21.4 (95% CI, 19.8-23.2) in the untreated hyperuricemia group. The PS-matched hazard ratio for composite CVD was 1.16 (95% CI, 0.99-1.34) in XOI initiators vs those with untreated hyperuricemia. In subgroup analyses, the PS-matched hazard ratio for composite CVD adjusted for serum uric acid levels was 1.10 (95% CI, 0.74-1.64) among XOI initiators. CONCLUSIONS: Among patients with gout, initiation of XOI was not associated with an increased or decreased cardiovascular risk compared with those with untreated hyperuricemia. Subgroup analyses adjusting for baseline uric acid levels also showed no association between XOI and cardiovascular risk.
Authors: Jane S Saczynski; Susan E Andrade; Leslie R Harrold; Jennifer Tjia; Sarah L Cutrona; Katherine S Dodd; Robert J Goldberg; Jerry H Gurwitz Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: Susan E Andrade; Leslie R Harrold; Jennifer Tjia; Sarah L Cutrona; Jane S Saczynski; Katherine S Dodd; Robert J Goldberg; Jerry H Gurwitz Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: Nam-Kyong Choi; Daniel H Solomon; Theodore N Tsacogianis; Joan E Landon; Hong Ji Song; Seoyoung C Kim Journal: J Bone Miner Res Date: 2017-02-07 Impact factor: 6.741
Authors: Anne E Nigra; Barbara V Howard; Jason G Umans; Lyle Best; Kevin A Francesconi; Walter Goessler; Richard Devereux; Ana Navas-Acien Journal: Environ Res Date: 2018-06-22 Impact factor: 6.498
Authors: Seoyoung C Kim; Tuhina Neogi; Eun Ha Kang; Jun Liu; Rishi J Desai; MaryAnn Zhang; Daniel H Solomon Journal: J Am Coll Cardiol Date: 2018-03-06 Impact factor: 24.094
Authors: MaryAnn Zhang; Daniel H Solomon; Rishi J Desai; Eun Ha Kang; Jun Liu; Tuhina Neogi; Seoyoung C Kim Journal: Circulation Date: 2018-09-11 Impact factor: 29.690
Authors: Tanya Keenan; Wei Zhao; Asif Rasheed; Weang K Ho; Rainer Malik; Janine F Felix; Robin Young; Nabi Shah; Maria Samuel; Nasir Sheikh; Megan L Mucksavage; Omar Shah; Jin Li; Michael Morley; Annika Laser; Nadeem Hayat Mallick; Khan Shah Zaman; Mohammad Ishaq; Syed Zahed Rasheed; Fazal-Ur-Rehman Memon; Faisal Ahmed; Bashir Hanif; Muhammad Shakir Lakhani; Muhammad Fahim; Madiha Ishaq; Naresh Kumar Shardha; Naveeduddin Ahmed; Khalid Mahmood; Waseem Iqbal; Saba Akhtar; Rabia Raheel; Christopher J O'Donnell; Christian Hengstenberg; Winifred März; Sekar Kathiresan; Nilesh Samani; Anuj Goel; Jemma C Hopewell; John Chambers; Yu-Ching Cheng; Pankaj Sharma; Qiong Yang; Jonathan Rosand; Giorgio B Boncoraglio; Shahana Urooj Kazmi; Hakon Hakonarson; Anna Köttgen; Andreas Kalogeropoulos; Philippe Frossard; Ayeesha Kamal; Martin Dichgans; Thomas Cappola; Muredach P Reilly; John Danesh; Daniel J Rader; Benjamin F Voight; Danish Saleheen Journal: J Am Coll Cardiol Date: 2016-02-02 Impact factor: 24.094